HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,133.252

+14.3791.29%

Number of Gainers:7

Number of Losers:4

Number of Flat:2

PE:- -

High:1,149.749

Open:1,118.873

Low:1,111.823

Close:1,118.873

Volume:102.30M

Turnover:1.02B

Market Cap:187.34B

Float Cap:139.78B

Loading ...

HAOHAI BIOTEC Reports 2025 Net Profit of 251 Million Yuan, Down 40.3% Year-on-Year

Returning Youth in Yunnan's Ruili Sparks Rural Prosperity with Ornamental Poultry

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

MT Newswires Live

FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

MT Newswires Live

Angelalign Technology to Hold Board Meeting on Annual Results and Final Dividend Recommendation

Fosun Pharmaceutical Amends Drug Licensing Agreements

MT Newswires Live

CMS Receives Initial "Buy" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth

BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

THOMSON REUTERS

China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days

THOMSON REUTERS

Ruili Border Crossing Records Over 110,000 Passenger Trips During Spring Festival

China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China

THOMSON REUTERS

CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application

China Medical System - Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis

THOMSON REUTERS

China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis

ANGELALIGN (06699) Asserts European Court's Preliminary Ruling on Specific Software Feature Has Minimal User Impact

Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal

Simply Wall St.

Xuanzhu Biopharmaceutical to Join Hang Seng Index

MT Newswires Live

Xuanzhu Biopharmaceutical Joins Hang Seng Composite IndexXuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1133.2516,"timestamp":1772179698737,"preClose":1118.8727,"halted":0,"volume":102303474,"delay":0,"changeRate":0.012851,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":14.378906,"latestTime":"02-27 16:00:00","open":1118.8727,"high":1149.7487,"low":1111.8226,"amount":1023675411,"amplitude":0.033897,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1772155800000,1772164800000],[1772168400000,1772179200000]],"pbRate":1.63126,"peRate":23.456739,"turnoverRate":0.004307,"increases":7,"decrements":6,"flats":0,"marketCap":187337209824,"floatMarketCap":139782862752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1149.7487,"amplitude":0.033897,"preClose":1118.8727,"low":1111.8226,"pbRate":"1.63126","latestPrice":1133.2516,"volume":102303474,"delay":0,"open":1118.8727,"prevYearClose":1094.978,"prevWeekClose":1191.344,"prevMonthClose":1146.099,"prevQuarterClose":1094.978,"fiveDayClose":1191.344,"twentyDayClose":1156.997,"sixtyDayClose":1264.759,"secType":"PLATE","market":"HK","turnoverRate":0.004307,"peRate":23.456739,"marketCap":187337209824,"floatMarketCap":139782862752,"timestamp":1772179698737,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":7,"down":4,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1166713382","title":"HAOHAI BIOTEC Reports 2025 Net Profit of 251 Million Yuan, Down 40.3% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1166713382","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166713382?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:26","pubTimestamp":1772188007,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) has announced its 2025 preliminary financial results. The company reported total operating revenue of approximately 2.473 billion yuan, representing a decrease of 8.33% compared...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","06826","BK1161"],"gpt_icon":0},{"id":"1142240992","title":"Returning Youth in Yunnan's Ruili Sparks Rural Prosperity with Ornamental Poultry","url":"https://stock-news.laohu8.com/highlight/detail?id=1142240992","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142240992?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:11","pubTimestamp":1772115107,"startTime":"0","endTime":"0","summary":"What is the value of a brilliantly feathered ornamental chicken? In Ruili City, Dehong Dai and Jingpo Autonomous Prefecture, Yunnan Province, Yan Ban, a De'ang ethnic youth born after 1995, recently...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02135","161022","BK1593","BK1209"],"gpt_icon":0},{"id":"2614041518","title":"Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041518","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041518?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:42","pubTimestamp":1772109753,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained approval from the China Securities Regulatory Commission to issue up to 6 billion yuan of bonds to professional investors, according to a Thursday Hong Kong bourse filing.The pharmaceutical firm can issue the bonds in multiple tranches within 24 months.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","US3Y.BOND","TLTW","BK1191","BK0188","600196","US12M.BOND","BK0187","BK1593","BK0012","BK0196","US10Y.BOND","BK0028","BK0060","US6M.BOND","US2Y.BOND","US30Y.BOND","BK0239","BK0096","US7Y.BOND","US5Y.BOND","BK0175","BK1515","TMF","BK0183"],"gpt_icon":0},{"id":"1176194664","title":"FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194664","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194664?lang=en_us&edition=fundamental","pubTime":"2026-02-26 18:40","pubTimestamp":1772102414,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that the company recently received approval from the China Securities Regulatory Commission (CSRC) for its application to issue science and technology innovation...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0183","BK1515","BK1593","BK0175","BK0060","BK1191","BK0239","02196","BK0187","BK0196","BK0012","BK0188","BK0028","600196"],"gpt_icon":0},{"id":"2614045081","title":"Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045081","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045081?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:23","pubTimestamp":1772022189,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Shanghai Fosun Pharmaceutical Industrial Development obtained clinical trial approval for Luvometinib Tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug will be tested in combination with Anlotinib for the treatment of patients with KRAS-mutant advanced non-small cell lung cancer.The subsidiary intends to begin the phase II study in China when the relevant conditions are fulfilled.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK1515","BK0188","BK0060","BK1191","BK0012","BK0187","02196","BK0096","BK0175","BK0196","BK1593","BK0028","BK0239","BK0183"],"gpt_icon":0},{"id":"2614704148","title":"Angelalign Technology to Hold Board Meeting on Annual Results and Final Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2614704148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614704148?lang=en_us&edition=fundamental","pubTime":"2026-02-25 17:05","pubTimestamp":1772010339,"startTime":"0","endTime":"0","summary":"Angelalign Technology Inc. will hold a board meeting on March 27, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025, their publication, and a possible final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelalign Technology Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7ppRTp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1593","06699","BK1583","BK1587"],"gpt_icon":0},{"id":"2614577290","title":"Fosun Pharmaceutical Amends Drug Licensing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2614577290","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614577290?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:39","pubTimestamp":1771997956,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) amended its licensing agreements for anti-cancer drug serplulimab.Subsidiary Henlius terminated its exclusive commercialization agreement with KGbi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","600196","BK0060","BK1191","BK0096","02196","BK0187","BK0175","BK0196","BK1593","BK0183","BK0188","BK0012","BK0239","BK0028"],"gpt_icon":0},{"id":"1179446439","title":"CMS Receives Initial \"Buy\" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1179446439","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179446439?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:12","pubTimestamp":1771985536,"startTime":"0","endTime":"0","summary":"Cinda Securities has issued a research report initiating coverage on CMS with a \"Buy\" rating. The firm forecasts the company's operating revenue for 2025-2027 to be RMB 8.216 billion, RMB 9.859...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","BK1191","00867","IE00BVYPNP33.GBP","BK1593","SG9999015978.USD","IE00BMCWC346.EUR","601059","IE00BVYPNQ40.USD","BK0276","LU2488822045.USD","SG9999015945.SGD","SG9999015952.SGD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2613712416","title":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712416","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712416?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:54","pubTimestamp":1771941265,"startTime":"0","endTime":"0","summary":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream AcceptedFeb 24 (Reuters) - China Medical System Holdings Ltd 0867.HK:CMS (867.HK/8A8.SG): NDA FOR ADDITIO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYV24P56.USD","IE00BMCWC346.EUR","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999004220.SGD","BK1593","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999015978.USD","SG9999015945.SGD","00867","SG9999015952.SGD","IE00BVYPNP33.GBP","BK1191"],"gpt_icon":0},{"id":"2613971404","title":"CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015945.SGD","BK1593","IE00BYV24P56.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015986.USD","LU2488822045.USD","SG9999015952.SGD","00867","BK1191","SG9999004220.SGD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613712833","title":"China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712833?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1593","SG9999015952.SGD","LU2488822045.USD","IE00BYV24P56.USD","SG9999015978.USD","IE00BVYPNQ40.USD","SG9999015986.USD","IE00BVYPNP33.GBP","00867","IE00BGHQDM52.EUR","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015945.SGD"],"gpt_icon":0},{"id":"1173924656","title":"Ruili Border Crossing Records Over 110,000 Passenger Trips During Spring Festival","url":"https://stock-news.laohu8.com/highlight/detail?id=1173924656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173924656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934712,"startTime":"0","endTime":"0","summary":"During the Spring Festival holiday period from February 15 to 23, the Ruili immigration border checkpoint recorded a total of 111,800 inbound and outbound passenger trips and 11,400 vehicle crossings...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02135","BK1209","BK1593"],"gpt_icon":0},{"id":"2613794373","title":"China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794373?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:53","pubTimestamp":1771926828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUE3RDXWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","LU2488822045.USD","SG9999015945.SGD","BK1191","IE00BMCWC346.EUR","IE00BYV24P56.USD","IE00BVYPNQ40.USD","SG9999015952.SGD","SG9999004220.SGD","SG9999015986.USD","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","00867"],"gpt_icon":0},{"id":"1104875656","title":"CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1104875656","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104875656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:52","pubTimestamp":1771926741,"startTime":"0","endTime":"0","summary":"CMS announced that its subsidiary, Demai Pharmaceutical, a specialist in dermatological health currently pursuing an independent listing on the Main Board of the Hong Kong Stock Exchange, has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","SG9999015986.USD","SG9999015945.SGD","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015978.USD","LU2488822045.USD","BK1593","06978","BK1161","BK1574","AD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","BK4132","BK1191","SG9999004220.SGD","SG9999015952.SGD","00867","159992"],"gpt_icon":0},{"id":"2613791083","title":"China Medical System  -  Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791083?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926544,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015978.USD","00867","LU2488822045.USD","SG9999004220.SGD","BK1191","BK1593","SG9999015945.SGD","SG9999015952.SGD","SG9999015986.USD","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2613791089","title":"China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791089?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:48","pubTimestamp":1771926492,"startTime":"0","endTime":"0","summary":"China Medical System Holdings said its subsidiary Dermavon Holdings received acceptance from China’s NMPA for a new drug application seeking an additional indication for ruxolitinib phosphate cream to treat mild to moderate atopic dermatitis, and the filing was granted priority review by the CDE. Dermavon holds an exclusive license from Incyte to develop, register and commercialize the product in Mainland China, Hong Kong, Macau, Taiwan and 11 Southeast Asian countries, with a non-exclusive manufacturing license in the same territory.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Ho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL4fHG48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","LU2488822045.USD","BK4588","BK1593","SG9999015986.USD","BK4139","BK4585","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BYV24P56.USD","BK4550","BK1191","BK4532","SG9999015952.SGD","INCY","SG9999004220.SGD","SG9999015978.USD","IE00BVYPNQ40.USD","00867","SG9999015945.SGD"],"gpt_icon":0},{"id":"1106284354","title":"ANGELALIGN (06699) Asserts European Court's Preliminary Ruling on Specific Software Feature Has Minimal User Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=1106284354","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106284354?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:52","pubTimestamp":1771897949,"startTime":"0","endTime":"0","summary":"ANGELALIGN TECHNOLOGY INC. (06699, hereinafter referred to as \"ANGELALIGN\") has stated that a provisional injunction issued by the Unified Patent Court of Düsseldorf, Germany, requiring the company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1583","BK1100","BK4588","VGT","BK4585","BK1587","06699"],"gpt_icon":0},{"id":"2613275621","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275621","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613275621?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:15","pubTimestamp":1771881333,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs.\nSee our latest analysis for China Medical System Holdings.\nThe stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004220.SGD","SG9999015945.SGD","SG9999015952.SGD","IE00BYV24P56.USD","IE00BMCWC346.EUR","AI","DCF","IE00BVYPNQ40.USD","BK1593","AIYY","BK4551","BK4585","IE00BGHQDM52.EUR","SG9999015986.USD","SG9999015978.USD","BK4587","IE00BVYPNP33.GBP","LU2488822045.USD","BK4023","BK1191","00867","BK4528","BK4588","BK4543"],"gpt_icon":0},{"id":"2613083972","title":"Xuanzhu Biopharmaceutical to Join Hang Seng Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2613083972","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613083972?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:01","pubTimestamp":1771812091,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group  said its non-wholly owned subsidiary Xuanzhu Biopharmaceutical  is due for inclusion to the Hang Seng Composite Index on March 9, according to a Hong Kong bourse filing Friday.Xuanzhu Biopharmaceutical went public in Hong Kong in October of last year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1515","BK1600","BK1593","02575","00460"],"gpt_icon":0},{"id":"2613222177","title":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613222177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613222177?lang=en_us&edition=fundamental","pubTime":"2026-02-22 18:06","pubTimestamp":1771754767,"startTime":"0","endTime":"0","summary":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026. Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL2nmBT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","BK1593","02575","BK1191","00460"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}